Relmada Therapeutics (RLMD) Stock Price
Relmada Therapeutics Price
Revenue at Relmada Therapeutics has contracted by 28.4% per year over the past 2 years to 5,129.00 USD. For Relmada Therapeutics, the net margin of -877.7% is down versus -100.0% a few years ago. The consensus 12-month price target for Relmada Therapeutics is 11.00 USD, about 187.2% above where the stock trades today. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus. The stock trades about 104% above its 52-week low.
Relmada Therapeutics stock price
Relmada Therapeutics business model & stock analysis
Frequently asked questions about Relmada Therapeutics
Relmada Therapeutics Inc is a pharmaceutical company that focuses on developing and commercializing innovative therapies for various medical conditions. Their business model revolves around researching and developing novel drug candidates, acquiring intellectual property rights, conducting clinical trials, and seeking regulatory approvals for their innovative products. By leveraging their expertise in drug development, Relmada aims to address unmet medical needs and improve patients' quality of life. Through collaborations and strategic partnerships, the company strives to bring their innovative therapies to market and generate value for their stakeholders.
Relmada Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Relmada Therapeutics Inc in the market include companies such as Johnson & Johnson, Pfizer Inc, Novartis AG, and Eli Lilly and Company.
Relmada Therapeutics Inc is a pharmaceutical company specializing in the development and commercialization of novel therapies for various diseases. Founded in 2012, Relmada focuses on innovative solutions to address unmet medical needs and improve patients' lives. The company's research and development efforts primarily concentrate on central nervous system (CNS) disorders, including chronic pain, addiction, and rare diseases. Relmada Therapeutics Inc has successfully advanced several promising drug candidates through preclinical and clinical trials, demonstrating its commitment to delivering effective and safe treatments. With its dedication to scientific advancements, Relmada Therapeutics Inc is poised to make a significant impact in the evolving healthcare industry.
Relmada Therapeutics Inc has achieved several significant milestones. The company successfully completed Phase 2 trials for its lead product, d-Methadone, for the treatment of neuropathic pain. In addition, Relmada Therapeutics received Fast Track designation from the U.S. Food and Drug Administration (FDA) for d-Methadone, which expedites the development and review process. The company also completed a successful IPO, raising $65 million in gross proceeds. Relmada Therapeutics continues to advance its pipeline, focusing on innovative therapies for central nervous system (CNS) disorders. With its groundbreaking achievements, Relmada Therapeutics Inc has positioned itself as a key player in the pharmaceutical industry.
Relmada Therapeutics Inc primarily operates in the United States.
Relmada Therapeutics Inc represents values of innovation, commitment to patient wellbeing, and scientific excellence. The company is dedicated to developing novel therapies to address unmet medical needs. Relmada focuses on advancing research and developing cutting-edge treatments to improve patients' quality of life. Their corporate philosophy revolves around collaboration, ethical practices, and a patient-centric approach. Relmada Therapeutics Inc believes in fostering partnerships and leveraging scientific expertise to create transformative healthcare solutions. Through their dedication to innovation and commitment to advancing medical science, Relmada aims to make a meaningful impact in improving patient outcomes and addressing global healthcare challenges.
Analysts currently set an average price target of 11.00 USD for the Relmada Therapeutics stock (median: 11.00 USD), implying +187.2 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the Relmada Therapeutics stock: 10 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Relmada Therapeutics to generate revenue of 10.00 M USD and earnings per share of -0.28 USD.
Converted at the current exchange rate, the Relmada Therapeutics share trades at 3.36 EUR (3.83 USD).
The Relmada Therapeutics share (RLMD) is listed on 3 stock exchanges, including: NASDAQ (RLMD), Frankfurt (4E2.F), München (4E2.MU).
Relmada Therapeutics Inc. is a biopharmaceutical company specializing in the development of novel therapeutics for central nervous system (CNS) disorders. The company is headquartered in New York City and offers a wide range of products and services tailored to the needs of patients and medical professionals. Relmada Therapeutics' business model is based on identifying, developing, and marketing innovative therapeutics for brain disorders and other psychiatric illnesses. The company holds a number of patents for developing biological therapeutics targeting various molecules within the human body. It has established an extensive network of partnerships with leading scientific and medical institutions to conduct a variety of clinical studies that help demonstrate the efficacy and safety of its products. Relmada Therapeutics' portfolio includes a range of novel therapeutics that can be used to treat a variety of psychiatric disorders. The company specializes in the development of preparations for the treatment of pain, depression, and addiction. Its flagship product is REL-1017, which targets the glutamatergic receptor and is currently in phase 3 clinical trials for the treatment of depression. In addition to its product pipeline, Relmada Therapeutics also offers a comprehensive range of services for medical professionals and patients. The company has a team of experienced clinical experts who assist customers in developing individualized treatment plans tailored to the specific needs of each patient. Relmada Therapeutics has also built a wide range of partnerships and alliances with key players in the pharmaceutical industry and healthcare. These partnerships enable the company to further expand its product development activities and improve the global marketing of its therapeutics. Overall, Relmada Therapeutics is an innovative biopharmaceutical company focused on improving the treatment of psychiatric disorders. Its comprehensive portfolio of products and services for medical professionals and patients, its experienced clinical experts, and its strong partnerships with other key players in the industry make it a significant player in the global market for psychiatric medications.
The expected revenue of Relmada Therapeutics is 10.00 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Relmada Therapeutics is -18.78 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Relmada Therapeutics is currently -13.92. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Relmada Therapeutics stock.
The price-to-sales ratio (P/S) of Relmada Therapeutics is currently 26.14. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Relmada Therapeutics stock.
The Eulerpool Quality Score for Relmada Therapeutics is 2/10.
The ISIN of Relmada Therapeutics is US75955J4022. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Relmada Therapeutics is A2PSZF. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Relmada Therapeutics is RLMD. The ticker symbol is used to trade Relmada Therapeutics shares on the stock exchange.
Relmada Therapeutics paid dividends every year for the past 0 years.
Relmada Therapeutics is assigned to the 'Health' sector.
The dividends of Relmada Therapeutics are distributed in USD.
Relmada Therapeutics stock
Relmada Therapeutics Peer Group
Relmada Therapeutics Ticker
Relmada Therapeutics FIGI
All fundamentals and in-depth analysis of Relmada Therapeutics
Our stock analysis for Relmada Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Relmada Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.